Torrent Pharmaceuticals has completed the acquisition of women healthcare brands Regestrone and Pregachieve for India from Swiss pharma major Novartis AG. The deal size is estimated to be around Rs 500 crore. Both the brands are prescribed by gynaecologists for management of abnormal uterine bleeding, peri and post menopausal symptoms and infertility.
The Ahmedabad-based company was in talks to acquire these brands since the last few months and had entered into a pact with Novartis last month to acquire the two brands.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.